Related Experiment Video
Updated: Dec 30, 2025
Cell-Free DNA Integrity Analysis in Urine Samples
Published on: January 5, 2017
Circulating cell-free DNA: Translating prostate cancer genomics into clinical care
Delila Gasi Tandefelt1, Johann de Bono2
1Sahlgrenska Cancer Center, University of Gothenburg, Sweden; Sahlgrenska University Hospital, Department of Urology, Gothenburg, Sweden.
Abstract:
Only in the past decade tremendous advances have been made in understanding prostate cancer genomics and consequently in applying new treatment strategies. As options regarding treatments are increasing so are the challenges in selecting the right treatment option for each patient and not the least, understanding the optimal time-point and sequence of applying available treatments. Critically, without reliable methods that enable sequential monitoring of evolving genotypes in individual patients, we will never reach effective personalised driven treatment approaches. This review focuses on the clinical implications of prostate cancer genomics and the potential of cfDNA in facilitating treatment management.
Insights
Advances in prostate cancer genomics offer new treatments. Circulating tumor DNA (ctDNA) monitoring is crucial for personalized treatment selection and management in prostate cancer patients.
Area of Science:
- Oncology
- Genomics
- Molecular Diagnostics
Background:
- Recent decade has seen significant progress in understanding prostate cancer genomics.
- Increasing treatment options present challenges in personalized treatment selection and sequencing.
- Effective personalized treatment requires reliable methods for monitoring evolving tumor genotypes.
Purpose of the Study:
- To review the clinical implications of prostate cancer genomics.
- To explore the potential of cell-free DNA (cfDNA) in guiding prostate cancer treatment management.
Main Methods:
- Review of current literature on prostate cancer genomics.
- Analysis of the role of cfDNA in monitoring treatment response and disease progression.
- Discussion of clinical applications of genomic insights and cfDNA analysis.
Main Results:
- Prostate cancer genomics provides insights into tumor heterogeneity and evolution.
- cfDNA analysis offers a non-invasive method for tracking genomic changes over time.
- Sequential cfDNA monitoring can inform treatment decisions and optimize therapeutic strategies.
Conclusions:
- Genomic understanding is revolutionizing prostate cancer care.
- cfDNA represents a promising tool for personalized treatment management.
- Integrating genomic data and cfDNA monitoring is key to advancing precision oncology in prostate cancer.
